GLP-1 Receptor Agonists and Aspiration Risk: From Universal Holding to Risk-Based Perioperative Management Review Abstract Purpose The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists has transformed the management of type 2 diabetes mellitus and obesity. As the use
Tag: Glucagon-like peptide-1 receptor agonists
Why GLP-1 Receptor Agonists Are Becoming Essential Cardiovascular Drugs
Why GLP-1 Receptor Agonists Are Becoming Essential Cardiovascular Drugs Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a transformative class of medications in the management of type 2 diabetes, demonstrating an approximate 14 percent reduction in major adverse cardiovascular events. Initially developed
